LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MabVax Therapeutics Holdings, Inc. (“MabVax” or “the Company”) (NASDAQ: MBVX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's shares between March 14, 2016 and May 18, 2018, inclusive (the “Class Period”), are encouraged to contact the firm before August 3, 2018.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, MabVax made materially false and/or misleading statements during the class period and failed to disclose the following facts: The Company’s internal controls for financial reporting were not sufficient, MabVax improperly calculated and reported beneficial ownership of its own shares, and allowed improper influence over the Company and its officers by certain shareholders. Due to these facts, MabVax’s financial statements and the Company’s public statements about its business operations were materially false and misleading. According to the lawsuit, when accurate information about the Company became apparent in the market, investors suffered damages.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.